Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 01 August 2006
Oxford Biomedica acquires Chiron patents
Oxford BioMedica has signed an agreement with Chiron to acquire certain patent families from Chiron's gene therapy patent portfolio
The agreement includes taking assignment of Chiron's interest in a license agreement with an undisclosed university Financial terms have not been disclosed
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Chiron's patent portfolio contains some early gene therapy technology that complements Oxford BioMedica's substantial gene therapy patent estate.
The technology acquired includes:.
1 - The use of human cell lines for the production of gene therapy products.
2 - Gene-directed enzyme pro-drug therapy (GDEPT).
3 - The use of the envelope protein of the vesicular stomatis virus (VSV-g) for increasing the ability of gene therapy vectors to transduce a broad range of human cell types.
Under a separate agreement, Chiron has made an equity investment in Oxford BioMedica subscribing for a total of 316,026 ordinary shares of 1p each at 17.23 pence per share.
Commenting on these agreements the company's senior vice president for commercial development, Peter Nolan, said: "We are delighted to have concluded this agreement with Chiron and welcome them as shareholders in the company".
"Securing this intellectual property will enhance our competitive position in gene therapy and in the use of our technology in drug discovery.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
